Showing results (61-70 of 82) with videos related to
Sort By:
Pageof 9
American Journal of Hematology|July 6, 2013
A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell diseaseAbdullah Kutlar, Marvin E Reid, Adlette Inati, et al.Pediatric Blood & Cancer|February 25, 2021
Pharmacokinetics and safety of ticagrelor in infants and toddlers with sickle cell disease aged <24 monthsBaba Psalm Duniva Inusa, Adlette Inati, Philip Maes, et al.Hemasphere|March 14, 2025
Selecting patients with sickle cell disease for gene addition or gene editing-based therapeutic approaches: Report on behalf of a joint EHA Specialized Working Group and EBMT Hemoglobinopathies Working Party consensus conferenceLucia de Franceschi, Franco Locatelli, David Rees, et al.The Lancet. Haematology|March 15, 2025
Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trialMiguel R Abboud, Rodolfo D Cançado, Mariane De Montalembert, et al.Pediatric Blood & Cancer|October 15, 2009
Pulmonary hypertension in children and young adults with sickle cell disease: evidence for familial clusteringHanane A Dahoui, Munya N Hayek, Paul J Nietert, et al.Journal of Clinical Medicine|November 21, 2019
Geographic Differences in Phenotype and Treatment of Children with Sickle Cell Anemia from the Multinational DOVE StudyBaba Psalm Duniya Inusa, Raffaella Colombatti, David C Rees, et al.Pediatric Blood & Cancer|July 30, 2021
Treatment-induced cerebral sinus venous thrombosis in childhood acute lymphoblastic malignancies: New risk factors to considerHabib El-Khoury, Omran Saifi, Salame Haddad, et al.Blood|July 18, 2022
Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 studyMatthew M Heeney, Miguel R Abboud, Jessie Githanga, et al.Blood|January 31, 2004
Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP studyRobert J Adams, Donald J Brambilla, Suzanne Granger, et al.Pediatric Blood & Cancer|April 22, 2022
Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 yearsJeremie H Estepp, Ram Kalpatthi, Gerald Woods, et al.Pageof 9